Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Convertible Debt (2016 - 2019)

Ani Pharmaceuticals' Convertible Debt history spans 9 years, with the latest figure at $117.6 million for Q3 2019.

  • For Q3 2019, Convertible Debt fell 12.33% year-over-year to $117.6 million; the TTM value through Sep 2019 reached $117.6 million, down 12.33%, while the annual FY2018 figure was $112.5 million, 12.28% down from the prior year.
  • Convertible Debt for Q3 2019 was $117.6 million at Ani Pharmaceuticals, up from $115.9 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $134.1 million in Q3 2018 and bottomed at $112.2 million in Q1 2015.
  • The 5-year median for Convertible Debt is $117.6 million (2019), against an average of $120.2 million.
  • The largest annual shift saw Convertible Debt rose 6.46% in 2015 before it dropped 12.33% in 2019.
  • A 5-year view of Convertible Debt shows it stood at $113.4 million in 2015, then increased by 6.36% to $120.6 million in 2016, then rose by 6.27% to $128.2 million in 2017, then decreased by 12.28% to $112.5 million in 2018, then rose by 4.56% to $117.6 million in 2019.
  • Per Business Quant, the three most recent readings for ANIP's Convertible Debt are $117.6 million (Q3 2019), $115.9 million (Q2 2019), and $114.2 million (Q1 2019).